Sanofi: positive results in treatment of asthma

(CercleFinance.com) - Sanofi and Regeneron announce that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 as a monotherapy has met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.


The trial also met a key secondary endpoint, demonstrating REGN3500 monotherapy significantly improved lung function compared to placebo. The incidence of serious adverse events and adverse events leading to treatment discontinuations was low.

The trial was a randomized, double-blind, placebo-controlled, 12-week proof-of-concept trial that enrolled 296 adult patients with moderate-to-severe asthma who were not well controlled on LABA and ICS therapy.


Copyright (c) 2019 CercleFinance.com. All rights reserved.